Clinical Trials Logo

Clinical Trial Summary

Rationale: Heart Failure (HF) elevated prevalence in Brasil and the world; 20-30% AHF patients develop CardioRenal Syndrome (CRS) type 1; Worsening Renal Failure (WRF) is a prognostic marker of mortality in Acute HF;NGAL is a novel biomarker of Acute Kidney Injury released in 2 hours, and addressed in several different clinical scenarios(contrast injury, cardiopulmonary bypass, critical illness.

Hypothesis: Admission NGAL predicts CRS in AHF patients admitted to the Emergency Room (ER).

Primary goal: To evaluate the diagnostic accuracy and the best cutoff value of urinary NGAL to predict the development of CRS type 1 in patients admitted to the Emergency Room.

Secondary goals: 1- To evaluate the prognostic impact of NGAL on in-hospital adverse outcomes (length of hospitalization, death, institution of renal replacement therapy, use of vasoactive drugs, mechanical ventilation).2- Evaluate the prognostic impact of NGAL in adverse outcomes in 30 days, 60 days and 6 months (death, rehospitalization, institution of renal replacement therapy).3- Identify clinical and hemodynamic characteristics of Acute HF that can influence the evolutionary behavior of NGAL levels in 48 hours.4- Identify the association of drugs commonly used for HF management, which might influence the evolutionary behavior of NGAL levels in 48 hours.5-Assess the impact of NGAL results in clinical decision making.

Methods: Observational, prospective, blinded study. Population: Acute HF patients admitted to the ER of Hospital Pró Cardiaco and Hospital Antonio Pedro - Universidade Federal Fluminense.

Statistics: Convenience Sample size (n=180); determination of best cut-off: ROC analysis; Predictive performance of the cut-off: sensibility, specificity, likelihood ratio, predictive value, accuracy; Identification of variables to predict CRS: logistic regression and square-Qui test; Correlations analysis of normally distributed variables: Pearson's linear correlation test; Mean values for normally distributed variables: Mann-Wittney test; Significance on p<0,05; Intra-assay variation analysis.

Study chronogram: Recruitment: 12 months; Results analysis and conclusions: 60 days; Manuscript preparation for paper submission: 30 days.


Clinical Trial Description

Rationale: Heart Failure (HF) elevated prevalence in Brasil and the world; 20-30% AHF patients develop CardioRenal Syndrome (CRS) type 1; Worsening Renal Failure (WRF) is a prognostic marker of mortality in Acute HF; available biomarker shows irreversible damage, late in CRS evolution.(creatinine);NGAL is a novel biomarker of Acute Kidney Injury released in 2 hours, and addressed in several different clinical scenarios(contrast injury, cardiopulmonary bypass, critical illness...); Acute HF patient's risk stratification will allow appropriate resource allocation and establishment of criteria for hospital admission and discharge.

Hypothesis: Admission NGAL predicts CRS in AHF patients admitted to the Emergency Room (ER).

Primary goal: To evaluate the diagnostic accuracy and the best cutoff value of urinary NGAL to predict the development of CRS type 1 in patients admitted to the Emergency Room.

Secondary goals: 1- To evaluate the prognostic impact of NGAL on in-hospital adverse outcomes (length of hospitalization, death, institution of renal replacement therapy, use of vasoactive drugs, mechanical ventilation).2- Evaluate the prognostic impact of NGAL in adverse outcomes in 30 days, 60 days and 6 months (death, rehospitalization, institution of renal replacement therapy).3- Identify clinical and hemodynamic characteristics of Acute HF that can influence the evolutionary behavior of NGAL levels in 48 hours.4- Identify the association of drugs commonly used for HF management, which might influence the evolutionary behavior of NGAL levels in 48 hours.5-Assess the impact of NGAL results in clinical decision making.

Methods: Observational, prospective, blinded study. Population: Acute HF patients admitted to the ER of Hospital Pró Cardiaco and Hospital Antonio Pedro - Universidade Federal Fluminense.

Statistics: Convenience Sample size (n=180); determination of best cut-off: ROC analysis; Predictive performance of the cut-off: sensibility, specificity, likelihood ratio, predictive value, accuracy; Identification of variables to predict CRS: logistic regression and square-Qui test; Correlations analysis of normally distributed variables: Pearson's linear correlation test; Mean values for normally distributed variables: Mann-Wittney test; Significance on p<0,05; Intra-assay variation analysis.

Study chronogram: Recruitment: 12 months; Results analysis and conclusions: 60 days; Manuscript preparation for paper submission: 30 days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01364636
Study type Observational
Source Pro-Cardiaco Hospital
Contact
Status Terminated
Phase
Start date February 2011
Completion date September 2012

See also
  Status Clinical Trial Phase
Suspended NCT04589065 - SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device) N/A
Not yet recruiting NCT02238093 - Cardiorenal Syndrome in End-Stage Kidney Disease N/A
Completed NCT01265615 - Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients Phase 4
Completed NCT03039959 - Predictive Value of Renal Venous Flow Profiles for Adverse Outcomes in Right Heart Failure
Suspended NCT03836482 - Selective Cytopheretic Device (SCD) Trial N/A
Recruiting NCT06111768 - Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study Phase 2
Withdrawn NCT02644057 - Dobutamaine Versus Milrinone in Cardiorenal Syndrome Phase 2
Completed NCT01570153 - Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial N/A
Completed NCT05927285 - Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1 N/A
Completed NCT03183323 - Implementation of Telerehabilitation In Support of HOme-based Physical Exercise for Heart Failure N/A
Completed NCT04917497 - Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock
Completed NCT04227977 - Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF) N/A
Recruiting NCT03684876 - Association Between Renal and Right Cardiac Functions After Urinary Sodium Depletion Following Cardiac Surgery
Completed NCT04393493 - The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide. Phase 2
Completed NCT04145635 - The Aortix CRS Pilot Study N/A
Completed NCT02372292 - Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure N/A
Completed NCT04116034 - Alfapump Direct Sodium Removal (DSR) Feasibility Study N/A
Terminated NCT00348556 - Use of Nesiritide (BNP) in Kidney Function in Patients With Congestive Heart Failure (CHF) and Kidney Failure Phase 1/Phase 2
Completed NCT03753607 - Renal Venous Flow and Cardiac Surgery-associated Acute Kidney Injury
Recruiting NCT05677100 - Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure N/A